All In Biotech

Drug Trial Radar · NCT05303519

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 365 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

365

Planned (sponsor's estimate)

Start

Jun 5, 2023

Primary completion

Dec 1, 2028

Study completion Dec 1, 2030

Sponsor

Lead sponsor
Nuvation Bio Inc.Industry
Sponsor type
Industry
Collaborators
AnHeart Therapeutics Inc.
First posted
Mar 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 2 or Grade 3 astrocytoma with high-risk features or IDH1-mutant Grade 4 astrocytoma, following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Part 2 will be randomized, double-blind, and placebo-controlled. The purpose of Part 3 will be to evaluate the efficacy of safusidenib in participants with residual or recurrent IDH1-mutant Grade 3 oligodendroglioma who have received surgery as their only treatment. Part 3 will be an open-label single-arm cohort and will enroll participants concurrently with Part 2.

Conditions

  • Glioma
  • Astrocytoma, Grade IV
  • IDH1-mutant Glioma
  • Astrocytoma, IDH-Mutant, Grade 3
  • Astrocytoma, IDH-Mutant, Grade 4
  • Astrocytoma, IDH-Mutant, Grade 2
  • Oligodendroglioma
  • Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted

Interventions

  • safusidenibDrug

    safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.

  • PlaceboDrug

    Placebo administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with placebo until disease progression or another reason for discontinuation occurs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: From participants sign ICF to 30 days after last dose,average 2 years
  2. Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0Time frame: From randomization until the date of first documented disease progression, average 2 years
  3. Part 3 Objective Response Rate (ORR) (Complete Response (CR), Partial Response (PR) and Minor Response (MR)) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0Time frame: From the first dose of study drug until the date of first documented disease progression, average 18 months

Locations

75 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama · Recruiting

  • Mayo Clinic - Arizona

    Phoenix, Arizona · Recruiting

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona · Recruiting

  • University of California San Diego

    La Jolla, California · Recruiting

  • University of California, Los Angeles

    Los Angeles, California · Recruiting

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California · Recruiting

  • Stanford University

    Palo Alto, California · Recruiting

  • University of California

    San Francisco, California · Recruiting

  • University of Colorado Health Cancer Care

    Aurora, Colorado · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • University of Florida Health

    Gainesville, Florida · Recruiting

  • Mayo Clinic - Florida

    Jacksonville, Florida · Recruiting

  • University of Miami Health

    Miami, Florida · Recruiting

  • Orlando Health Cancer Institute

    Orlando, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Northwestern Medicine Robert H. Lurie Comprehensive Cancer Center

    Chicago, Illinois · Not yet recruiting

  • University of Chicago

    Chicago, Illinois · Not yet recruiting

  • Indiana University

    Indianapolis, Indiana · Recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • University of Kentucky

    Lexington, Kentucky · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Mayo Clinic - Rochester

    Rochester, Minnesota · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Billings Clinic

    Billings, Montana · Recruiting

  • Rutgers Cancer Institute

    New Brunswick, New Jersey · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of Rochester Medical Center

    Rochester, New York · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center

    Winston-Salem, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Oregon Health Science University

    Portland, Oregon · Recruiting

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • OneOncology Research Network

    Nashville, Tennessee · Not yet recruiting

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.